MS
CBMG

Mizuho Securities’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Mizuho Securities’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-300
Closed -$5K – 177
2019
Q2 		$5K Buy
+300
New +$4.9K 0.01% 143

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mizuho Securities's CBMG Position: Q3 2019 in Review

Mizuho Securities sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2019, closing a stake of 300 shares — an estimated $5K sold.

Mizuho Securities first reported a position in CBMG in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 40 funds tracked by Wall St. Rank hold CBMG as of Q3 2019.

  • Mizuho Securities reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2019 after selling out during the quarter.
  • Mizuho Securities sold 300 Cellular Biomedicine Group, Inc. shares in Q3 2019, an estimated $5K.
  • Mizuho Securities first reported a position in Cellular Biomedicine Group, Inc. in Q2 2019 and held it in 1 quarter.
  • Mizuho Securities's Cellular Biomedicine Group, Inc. position peaked at $5K in Q2 2019.
  • 40 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2019.

Based on Mizuho Securities's 13F filing for Q3 2019, filed 14 Nov 2019.